Table 3.
Detailed description in patients who experienced graft rejection
| No. | Donor | Conditioning | Age (yr) | Diagnosis | CD34 dose | CD3 dose | HLA | CD3+ on day +28 | Week2 CSPb | MMFa
|
||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MMF frequency | total MPA Css | Unbound MPA Css | ||||||||||
| 1 | Sibling | TBI | 53.8 | MM | 10.87 | 3.29 | Identical | 15 | 437 | Q12hr | 4.30 | NA |
| 2 | Unrelated | FLU/TBI | 60.1 | CML | 6.28 | 1.18 | A, B, C, DRB1, DQB1 | 15 | 443 | Q12hr | 1.15 | 20.65 |
| 3 | Unrelated | FLU/TBI | 45.3 | AML | 0.76 | 0.31 | A, B, C, DRB1, DQB1 | 9 | 502 | Q8hr | 2.47 | 34.88 |
| 4 | Unrelated | FLU/TBI | 40 | MDS | 1.48 | 1.47 | A, B, C, DRB1, DQB1 | 0 | 309 | Q12hr | 1.74 | 10.71 |
| 5 | Unrelated | FLU/TBI | 46.6 | NHL | 7.77 | 3.62 | A, B, C, DRB1, DQB1 | 59 | 576 | Q12hr | 2.42 | 19.24 |
| 6 | Sibling | FLU/TBI | 62.8 | NHL and MDS | 33.75 | 4.57 | Identical | 75 | 584 | Q12hr | 1.48 | 12.45 |
| 7 | Unrelated | FLU/TBI | 48.5 | CLL | 4.90 | 3.04 | A, B, C, DRB1, DQB1 | 1 | 339 | Q12hr | 1.95 | 14.18 |
| 8 | Unrelated | FLU/TBI | 38.6 | CML | 6.44 | 1.61 | A, B, C, DRB1, DQB1 | 40 | 350 | Q12hr | 1.68 | 17.99 |
| 9 | Unrelated | FLU/TBI | 60 | NHL | 4.08 | 1.25 | A, B, DRB1, DQB1; C antigen mistmatch | 30 | 459 | Q8hr | 2.32 | 20.28 |
a
Abbreviations: acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), calcineurin inhibitor (CNI), cyclosporine (CSP), fludarabine monophosphate (FLU), human leukocyte antigen (HLA), myelodysplastic syndrome (MDS), multiple myeloma (MM), mycophenolate mofetil (MMF), mycophenolic acid (MPA), Non-Hodgkin’s lymphoma (NHL), total body irradiation (TBI).
b
Rejections only occurred in patients receiving CSP.